Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Recruiting 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Sarcoma 1Recurrence 1Neoplasm Metastasis 1Brest Cancer 1

Interventions

Injections 3Doxorubicin 3anlotinib 2toripalimab 1pemigatinib 1pazopanib 1montelukast 1liposomal doxorubicin 1eribulin 1chlorhexidine gluconate 1camrelizumab 1bexmarilimab 1apatinib 1X-Rays 1Trabectedin 1Temozolomide 1Tablets 1Sodium Chloride 1Radiotherapy 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Negative-Pressure Wound Therapy 1KP 1339 1Ipilimumab 1Immunotherapy 1Heavy Ion Radiotherapy 1Granulocyte Colony-Stimulating Factor 1Epirubicin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Sarcoma × eribulin × Clear all
NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

Fudan University

Phase 2 Not yet recruiting
46 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡